Program
Nivolumab
Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.
Drug pageNivolumab: every studyMany companies study it; this page follows only the 145 they lead. All 1,032 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 12410 open or running | phase 4since Nov 2, 2015 | Feb 27, 2007 | Feb 5, 2027phase 2 · NCT06946797 |
| Ono Pharmaceuticalits history only | 144 open or running | phase 3since Oct 9, 2014 | Jan 26, 2009 | Dec 31, 2027phase 2 · NCT04566380 |
| Pfizerits history only | 20 open or running | phase 2since Oct 7, 2015 | Oct 7, 2015 | none ahead |
| Ella Therapeuticsits history only | 10 open or running | phase 2since Aug 13, 2020 | Aug 13, 2020 | none ahead |
| ExcellaBioits history only | 10 open or running | phase 2since Oct 20, 2017 | Oct 20, 2017 | none ahead |
| Nilogen Oncosystemsits history only | 10 open or running | early phase 1since Dec 3, 2017 | Dec 3, 2017 | none ahead |
| Rampart Healthits history only | 10 open or running | phase 2since Aug 9, 2019 | Aug 9, 2019 | none ahead |
| USWM CT | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics, Medarex, Parexel, Astellas Pharma, Akamis Bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of USWM CT only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 26, 2022First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT05601752 · 21 enrolled · United States, Canada, France and more
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The one study USWM CT leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05601752Ovarian Neoplasms · United States, Canada, France and more | 2 | Terminated | Sep 30, 2025 | 21 |
How it is read
Names in the registry
- “Nivolumab”, 115 entries
- “nivolumab”, 18 entries
- “ONO-4538”, 13 entries
- “BMS-936558 (MDX-1106)”, 5 entries
- “Nivolumab + Relatlimab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 36 studies
- Melanoma, 21 studies
- Carcinoma, Renal Cell, 11 studies
- Carcinoma, Hepatocellular, 6 studies
- Colorectal Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.